Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 1,601–1,700 of 10,906
Routhu, N. K., Gangadhara, S., Lai, L., Davis-Gardner, M. E., Floyd, K. A., Shiferaw, A., Bartsch, Y. C., Fischinger, S., Khoury, G., Rahman, S. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo0226 · Cited by 51
Recent advances in therapeutic nucleic acids and their analytical methods
Talap, J., Zhao, J. Y., Shen, M., Song, Z., Zhou, H., Kang, Y., Sun, L., Yu, L., Zeng, S., & Cai, S. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114368 · Cited by 56
Self-citationA review of adverse effects of COVID-19 vaccines
Mushtaq, H. A., Khedr, A., Koritala, T., Bartlett, B. N., Jain, N. K., & Khan, S. A. (2022) · Infezioni in Medicina · doi:10.53854/liim-3001-1 · Cited by 66
Evaluation of Messenger RNA From COVID-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk
Golan, Y., Prahl, M. K., Cassidy, A. G., et al. (2021) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2021.1929 · Cited by 50
Flacco, M. E., Soldato, G., Martellucci, C. A., Carota, R., Luzio, R. D., Caponetti, A., & Manzoli, L. (2021) · Vaccines · doi:10.3390/vaccines9060628 · Cited by 52
An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology
Gresham, L. M., Marzario, B., Dutz, J. P., & Kirchhof, M. G. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.01.047 · Cited by 51
Change in age distribution of COVID-19 deaths with the introduction of COVID-19 vaccination
Pastorino, R., Pezzullo, A. M., Villani, L., Causio, F. A., Axfors, C., Contopoulos‐Ioannidis, D. G., Boccia, S., & Ioannidis, J. P. A. (2021) · Environmental Research · doi:10.1016/j.envres.2021.112342 · Cited by 44
Tai, W., Yang, K., Liu, Y., Li, R., Feng, S., Chai, B., Zhuang, X., Qi, S., Shi, H., Liu, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43798-8 · Cited by 54
Chen, G., Li, X., Sun, M., Zhou, Y., Yin, M., Zhao, B., & Li, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669010 · Cited by 49
Littler, D. R., Liu, M., McAuley, J., Lowery, S. A., Illing, P. T., Gully, B. S., Purcell, A. W., Chandrashekaran, I. R., Perlman, S. M., Purcell, D. F. J., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101362 · Cited by 52
Pegoraro, C., Domingo-Ortí, I., Conejos‐Sánchez, I., & Vicent, M. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115195 · Cited by 59
Shin, K., Suh, H., Grundler, J., Lynn, A. Y., Pothupitiya, J. U., Moscato, Z. M., Reschke, M., Bracaglia, L. G., Piotrowski-Daspit, A. S., & Saltzman, W. M. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121676 · Cited by 50
Yam‐Puc, J. C., Hosseini, Z., Horner, E. C., Gerber, P. P., Beristain‐Covarrubias, N., Hughes, R., Lulla, A., Rust, M., Boston, R. H., Ali, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38810-0 · Cited by 56
Zothantluanga, J. H., Abdalla, M., Rudrapal, M., Tian, Q., Chetia, D., & Li, J. (2022) · Polycyclic aromatic compounds · doi:10.1080/10406638.2022.2046613 · Cited by 63
Higdon, M. M., Wahl, B., Jones, C., Rosen, J., Truelove, S., Baidya, A., Nande, A., ShamaeiZadeh, P., Walter, K., Feikin, D., et al. (2021) · medRxiv · doi:10.1101/2021.09.17.21263549 · Cited by 122
Hobohm, L., Sagoschen, I., Barco, S., Schmidtmann, I., Espinola-Klein, C., Konstantinides, S., Münzel, T., & Keller, K. (2022) · Viruses · doi:10.3390/v14020275 · Cited by 42
Tsilingiris, D., Vallianou, N. G., Karampela, Ι., Liu, J., & Dalamaga, Μ. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100159 · Cited by 51
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
Moga, E., Lynton‐Pons, E., & Domingo, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904686 · Cited by 52
Talotta, R., & Robertson, E. S. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.05.001 · Cited by 52
Bouton, T. C., Lodi, S., Turcinovic, J., Schaeffer, B., Weber, S. E., Quinn, E., Korn, C., Steiner, J., Schechter-Perkins, E. M., Duffy, E., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab465 · Cited by 49
Miyashita, K., Hozumi, H., Furuhashi, K., Nakatani, E., Inoue, Y., Yasui, H., Karayama, M., Suzuki, Y., Fujisawa, T., Enomoto, N., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2155250 · Cited by 50
Zhou, R., Wang, P., Wong, Y.-C., Xu, H., Lau, S.-Y., Liu, L., Mok, B. W.-Y., Peng, Q., Liu, N., Woo, K. F., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103762 · Cited by 52
Omo‐Lamai, S., Wang, Y., Patel, M. N., Essien, E., Shen, M., Majumdar, A., Espy, C. L., Wu, J., Channer, B., Tobin, M. P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.16.589801 · Cited by 48
Lipid nanoparticle-mediated mRNA delivery to CD34+ cells in rhesus monkeys
Kim, H., Zenhausern, R., Gentry, K., Lian, L., Huayamares, S. G., Radmand, A., Loughrey, D., Podilapu, A. R., Hatit, M. Z. C., Ni, H., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02470-2 · Cited by 72
Jörrißen, P., Schütz, P., Weiand, M., Vollenberg, R., Schrempf, I. M., Ochs, K., Frömmel, C., Tepasse, P., Schmidt, H., & Zibert, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679841 · Cited by 53
On the role of data, statistics and decisions in a pandemic
Jahn, B., Friedrich, S., Behnke, J., Engel, J., Garczarek, U., Münnich, R. T., Pauly, M., Wilhelm, A., Wolkenhauer, O., Zwick, M., et al. (2022) · AStA Advances in Statistical Analysis · doi:10.1007/s10182-022-00439-7 · Cited by 59
Analytical techniques for the characterization of nanoparticles for mRNA delivery
Nogueira, S. S., Samaridou, E., Simon, J., Simon, F., Beck‐Broichsitter, M., & Mehta, A. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114235 · Cited by 61
An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era
Pascual‐Iglesias, A., Cantón, J., Ortega‐Prieto, A. M., Jiménez-Guardeño, J. M., & Regla-Nava, J. Á. (2021) · Pathogens · doi:10.3390/pathogens10081030 · Cited by 53
Current and prospective computational approaches and challenges for developing COVID-19 vaccines
Hwang, W., Lei, W., Katritsis, N. M., MacMahon, M., Chapman, K. L., & Han, N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.004 · Cited by 52
Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2
Magen, E., Yakov, A., Green, I., Israel, A., Vinker, S., & Merzon, E. (2022) · Allergy and Asthma Proceedings · doi:10.2500/aap.2022.43.210111 · Cited by 58
Nano-Microparticle Platforms in Developing Next-Generation Vaccines
Cappellano, G., Abreu, H., Casale, C., Dianzani, U., & Chiocchetti, A. (2021) · Vaccines · doi:10.3390/vaccines9060606 · Cited by 53
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Chalkias, S., Harper, C., Vrbicky, K. W., Walsh, S. R., Essink, B. J., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38892-w · Cited by 49
Self-citationOrthogonal Light-Activated DNA for Patterned Biocomputing within Synthetic Cells
Hartmann, D., Chowdhry, R., Smith, J. M., & Booth, M. J. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c02350 · Cited by 54
Lozano‐Rodríguez, R., Valentín‐Quiroga, J., Ortiz, J. A., Martín‐Quirós, A., Pascual‐Iglesias, A., Terrón‐Arcos, V., Montalbán-Hernández, K. M., Casalvilla‐Dueñas, J. C., Bergón-Gutiérrez, M., Alcamí, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110235 · Cited by 54
Cantrelle, F., Boll, E., Brier, L., Moschidi, D., Belouzard, S., Landry, V., Leroux, F., Dewitte, F., Landrieu, I., Dubuisson, J., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202109965 · Cited by 50
Ryan, F. J., Norton, T. S., McCafferty, C., Blake, S. J., Stevens, N. E., James, J., Eden, G. L., Tee, Y. C., Benson, S. C., Masavuli, M. G., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100971 · Cited by 63
Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 56
Yamana, T. K., Galanti, M., Pei, S., Fusco, M. D., Angulo, F. J., Moran, M. M., Khan, F. L., Swerdlow, D. L., & Shaman, J. L. (2023) · PLoS ONE · doi:10.1371/journal.pone.0275699 · Cited by 51
Davies, S. P., Mycroft‐West, C. J., Pagani, I., Hill, H. J., Chen, Y., Karlsson, R. T. G., Bagdonaite, I., Guimond, S. E., Stamataki, Z., de Lima, M. A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.660490 · Cited by 47
Xu, K., Dai, L., & Gao, G. F. (2021) · International Immunology · doi:10.1093/intimm/dxab061 · Cited by 51
Woo, W., Kim, A. Y., Yon, D. K., Lee, S. W., Hwang, J., Jacob, L., Koyanagi, A., Kim, M. S., Moon, D. H., Jung, J. W., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27501 · Cited by 52
mRNA therapy at the convergence of genetics and nanomedicine
Conde, J., Langer, R., & Rueff, J. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01347-w · Cited by 51
Toward Gene Transfer Nanoparticles as Therapeutics
Kavanagh, E. W., & Green, J. J. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102145 · Cited by 48
van Doremalen, N., Schulz, J. E., Adney, D. R., Saturday, T. A., Fischer, R. J., Yinda, C. K., Thakur, N., Newman, J., Ulaszewska, M., Belij‐Rammerstorfer, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32248-6 · Cited by 42
Danese, E., Montagnana, M., Salvagno, G. L., Gelati, M., Peserico, D., Pighi, L., NITTO, S. D., Henry, B. M., Porru, S., & Lippi, G. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0339 · Cited by 65
Yamamoto, S., Maeda, K., Matsuda, K., Tanaka, A., Horii, K., Okudera, K., Takeuchi, J. S., Mizoue, T., Konishi, M., Ozeki, M., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1048 · Cited by 56
Kim, Y., Landstrom, A. P., Shah, S. H., Wu, J. C., & Seidman, C. E. (2024) · Circulation · doi:10.1161/cir.0000000000001296 · Cited by 91
Follmann, D. A., Fintzi, J., Fay, M. P., Janes, H., Baden, L. R., Sahly, H. M. E., Fleming, T. R., Mehrotra, D. V., Carpp, L. N., Juraska, M., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-8149 · Cited by 53
Self-citationBierle, D. M., Ganesh, R., Tulledge‐Scheitel, S. M., Hanson, S. N., Arndt, L. L., Wilker, C. G., & Razonable, R. R. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab570 · Cited by 46
Upadhyay, V., Lucas, A., Panja, S., Miyauchi, R., & Mallela, K. M. G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101208 · Cited by 44
Israeli, M., Finkel, Y., Yahalom-Ronen, Y., Paran, N., Chitlaru, T., Israeli, O., Cohen-Gihon, I., Aftalion, M., Falach, R., Rotem, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29896-z · Cited by 48
Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces
Kwok, H. F. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59170 · Cited by 53
SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques
Garrido, C., Curtis, A. D., Dennis, M. L., Pathak, S., Gao, H., Montefiori, D. C., Tomai, M. A., Fox, C. B., Kozlowski, P. A., Scobey, T., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj3684 · Cited by 47
Self-citationKahn, R. J., Holmdahl, I. E., Reddy, S. C., Jernigan, J. A., Mina, M. J., & Slayton, R. B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab517 · Cited by 51
COVID-19 Vaccination and The Eye
Wang, M. T. M., Niederer, R. L., McGhee, C. N. J., & Danesh-Meyer, H. V. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.02.011 · Cited by 50
Tragni, V., Preziusi, F., Laera, L., Onofrio, A., Mercurio, I., Todisco, S., Volpicella, M., Grassi, A., & Pierri, C. L. (2022) · The EPMA Journal · doi:10.1007/s13167-021-00267-w · Cited by 52
Gordon, C. J., Lee, H. W., Tchesnokov, E. P., Perry, J. K., Feng, J. Y., Bilello, J. P., Porter, D., & Götte, M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101529 · Cited by 49
Mouliou, D. S., & Dardiotis, E. (2022) · Diagnostics · doi:10.3390/diagnostics12071555 · Cited by 55
SARS-CoV-2 Vaccine–induced Thyroiditis: Safety of Revaccinations and Clinical Follow-up
Oğuz, S. H., Şendur, S. N., İremli, B. G., Gürlek, A., Erbas, T. A., & Ünlütürk, U. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac049 · Cited by 53
Nucleic acid-based drugs for patients with solid tumours
Huayamares, S. G., Loughrey, D., Kim, H., Dahlman, J. E., & Sorscher, E. J. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00883-1 · Cited by 61
Shimizu, J., Sasaki, T., Koketsu, R., Morita, R., Yoshimura, Y., Murakami, A., Saito, Y., Kusunoki, T., Samune, Y., Nakayama, E. E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19993-w · Cited by 53
Spinelli, F. R., Favalli, E. G., Garufi, C., Cornalba, M., Colafrancesco, S., Conti, F., & Caporali, R. F. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02674-w · Cited by 49
Cordeiro, A. S., Patil‐Sen, Y., Shivkumar, M., Patel, R., Khedr, A., & Elsawy, M. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122091 · Cited by 59
Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination
Sokal, A., Bastard, P., Chappert, P., Spaeth, G. B., Fourati, S., Vandenberghe, A., Lagouge-Roussey, P., Meyts, I., Gervais, A., Bouvier‐Alias, M., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220258 · Cited by 50
Putative Role of Vitamin D for COVID-19 Vaccination
Chiu, S.-K., Tsai, K., Wu, C., Zheng, C., Yang, C., Hu, W., Hou, Y., Lu, K., & Chao, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168988 · Cited by 56
Bruxvoort, K. J., Sy, L. S., Qian, L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3916094 · Cited by 48
Oseran, A. S., Song, Y., Xu, J., Dahabreh, I. J., Wadhera, R. K., de Lemos, J. A., Das, S. R., Sun, T., Yeh, R. W., & Kazi, D. S. (2023) · BMJ · doi:10.1136/bmj-2023-076222 · Cited by 49
New-Onset and Relapsed Kidney Histopathology Following COVID-19 Vaccination: A Systematic Review
Wu, H. H. L., Kalra, P. A., & Chinnadurai, R. (2021) · Vaccines · doi:10.3390/vaccines9111252 · Cited by 52
SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses
Carnell, G., Ciazynska, K. A., Wells, D. A., Xiong, X., Aguinam, E. T., McLaughlin, S. H., Mallery, D. L., Ebrahimi, S., Ceron‐Gutierrez, L., Asbach, B., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00203-21 · Cited by 48
Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines
Lim, C. M. L., Komarasamy, T. V., Adnan, N. A. A., Radhakrishnan, A. K., & Balasubramaniam, V. R. M. T. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13276 · Cited by 66
Next generation self-replicating RNA vectors for vaccines and immunotherapies
Aliahmad, P., Miyake-Stoner, S. J., Geall, A. J., & Wang, N. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00435-8 · Cited by 55
Farroni, C., Diamanti, A. P., Aiello, A., Nicastri, E., Laganà, B., Agrati, C., Castilletti, C., Meschi, S., Colavita, F., Cuzzi, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.846753 · Cited by 52
COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series
Ruan, Z., Tang, Y., Li, C., Sun, C., Zhu, Y., Li, Z., & Chang, T. (2021) · Vaccines · doi:10.3390/vaccines9101112 · Cited by 49
Liu, B. D. X., Ugolini, C., & Jha, P. (2021) · Cureus · doi:10.7759/cureus.16172 · Cited by 47
Drug-Induced Liver Injury After COVID-19 Vaccine
Mann, R., Sekhon, S., & Sekhon, S. S. (2021) · Cureus · doi:10.7759/cureus.16491 · Cited by 47
From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines
Lopez-Cantu, D. O., Wang, X., Carrasco-Magallanes, H., Afewerki, S., Zhang, X., Bonventre, J. V., & Ruiz‐Esparza, G. U. (2022) · Nano-Micro Letters · doi:10.1007/s40820-021-00771-8 · Cited by 53
Ruddy, J. A., Boyarsky, B. J., Werbel, W. A., Bailey, J. R., Karaba, A. H., Garonzik‐Wang, J., Segev, D. L., & Durand, C. M. (2021) · AIDS · doi:10.1097/qad.0000000000002945 · Cited by 49
The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune escape, and response strategies
Lu, Y., Ao, D., He, X., & Wei, X. (2024) · MedComm · doi:10.1002/mco2.675 · Cited by 64
Disparities in COVID-19 vaccine uptake among health care workers
Farah, W. H., Breeher, L. E., Shah, V. P., Hainy, C. M., Tommaso, C. P., & Swift, M. D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.045 · Cited by 52
Diallo, B., Chasaide, C. N., Wong, T. Y., Schmitt, P., Lee, K. S., Weaver, K. L., Miller, O. A., Cooper, M., Jazayeri, S. D., Damron, F. H., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00665-3 · Cited by 51
Moon, A. M., Webb, G. J., García‐Juárez, I., Kulkarni, A. V., Adalı, G., Wong, D., Lusina, B., Dalekos, G. Ν., Masson, S., Shore, B. M., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1853 · Cited by 48
Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications
Dhayalan, M., Wang, W., Riyaz, S. U. M., Dinesh, R. A., Shanmugam, J., Irudayaraj, S. S., Stalin, A., Giri, J. P., Mallik, S., & Hu, R. (2024) · 3 Biotech · doi:10.1007/s13205-023-03901-8 · Cited by 57
Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery
Haque, M. A., Shrestha, A., Mikelis, C. M., & Mattheolabakis, G. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100283 · Cited by 102
Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here
Halperin, D. T., Hearst, N., Hodgins, S., Bailey, R. C., Klausner, J. D., Jackson, H., Wamai, R. G., Ladapo, J. A., Over, M., Baral, S., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-12082-z · Cited by 61
Desmecht, S., Tashkeev, A., Moussaoui, M. E., Maréchal, N., Perée, H., Tokunaga, Y., Fombellida-Lopez, C., Polese, B., Legrand, C., Wéry, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863554 · Cited by 52
Butsch, W. S., Hajduk, A. M., Cardel, M. I., Donahoo, W. T., Kyle, T. K., Stanford, F. C., Zeltser, L. M., Kotz, C. M., & Jastreboff, A. M. (2021) · Obesity · doi:10.1002/oby.23251 · Cited by 49
COVID-19 vaccine use in immunocompromised patients: A commentary on evidence and recommendations
Duly, K., Farraye, F. A., & Bhat, S. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab344 · Cited by 52
Sex-disaggregated data in COVID-19 vaccine trials
Vijayasingham, L., Bischof, E. Y., & Wolfe, J. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00384-6 · Cited by 51
COVID-19 mRNA Vaccination–Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PET/CT
Xu, G., & Lü, Y. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003597 · Cited by 47
Programmable RNA Loading of Extracellular Vesicles with Toehold-Release Purification
Malle, M. G., Song, P., Löffler, P. M. G., Kalisi, N., Yan, Y., Valero, J., Vogel, S., & Kjems, J. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c13123 · Cited by 56
Olfactory immunology: the missing piece in airway and CNS defence
Wellford, S. A., & Moseman, E. A. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00972-9 · Cited by 57
Valcarce, V., Stafford, L. S., Neu, J., Cacho, N. T., Parker, L. A., Mueller, M., Burchfield, D. J., Li, N., & Larkin, J. (2021) · Breastfeeding Medicine · doi:10.1089/bfm.2021.0122 · Cited by 50
Lv, K., Yu, Z., Wang, J., Li, N., Wang, A., Xue, T., Wang, Q., Shi, Y., Han, L., Qin, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202404684 · Cited by 64
Long, S. W., Olsen, R. J., Christensen, P. A., Subedi, S., Olson, R., Davis, J. J., Saavedra, M. O., Yerramilli, P., Pruitt, L., Reppond, K., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.03.004 · Cited by 47
Optimal control of the spatial allocation of COVID-19 vaccines: Italy as a case study
Lemaitre, J. C., Pasetto, D., Zanon, M., Bertuzzo, E., Mari, L., Miccoli, S., Casagrandi, R., Gatto, M., & Rinaldo, A. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010237 · Cited by 49
Kar, S., Devnath, P., Emran, T. B., Tallei, T. E., Mitra, S., & Dhama, K. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.604 · Cited by 50
Gagné, M., Moliva, J. I., Foulds, K., Andrew, S., Flynn, B., Werner, A. P., Wagner, D. A., Teng, I.-T., Lin, B. C., Moore, C., et al. (2022) · bioRxiv · doi:10.1101/2022.02.03.479037 · Cited by 77
Self-citationVaccine approaches for antigen capture by liposomes
Zhou, S., Luo, Y., & Lovell, J. F. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2274479 · Cited by 55
Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines
Zinatizadeh, M. R., Zarandi, P. K., Zinatizadeh, M., Yousefi, M. H., Amani, J., & Rezaei, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112527 · Cited by 56
B Cell Depletion and SARS‐CoV ‐2 Vaccine Responses in Neuroimmunologic Patients
Kornek, B., Leutmezer, F., Rommer, P. S., Koblischke, M., Schneider, L., Haslacher, H., Thalhammer, R., Zimprich, F., Zulehner, G., Bsteh, G., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26309 · Cited by 53
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.